Fig. 4: Clinical outcomes in participants with mRCC treated with cabozantinib + nivolumab with or without CBM588. | Nature Medicine

Fig. 4: Clinical outcomes in participants with mRCC treated with cabozantinib + nivolumab with or without CBM588.

From: Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial

Fig. 4

a, ORR. b, Best change in target lesions. c, PFS. The data are from n = 29 participants (19 participants in the cabozantinib + nivolumab with CBM588 arm and 10 participants in the cabozantinib + nivolumab arm). The Kaplan–Meier log-rank test was used to compare survival between the two arms.

Back to article page